Limits...
Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.

Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X, Liu F, Wu M, Deng G, Ding W, Jia H, Li Z - Cancer Sci. (2014)

Bottom Line: We further examined its effect on the response to chemotherapeutic drugs in the Reh and RS4;11 cell lines.A significantly poorer treatment outcome (P < 0.05) was found in the low-expression group and verified in the validation cohort (76 cases, P < 0.05).Increasing/decreasing miR-210 expression using agomir/antagomir could enhance or reduce the response of Reh cells and RS4;11 cells to daunorubicin/dexamethasone/L-asparaginase and daunorubicin/dexamethasone/vincristine, respectively.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Major Diseases in Children (Capital Medical University), Ministry of Education, National Key Discipline of Pediatrics, Ministry of Education, Hematology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.

Show MeSH

Related in: MedlinePlus

The prognostic significance of miR-210 in the validation cohort (76 patients). The dashed line and solid line were derived from miR-210 high-expression or low-expression group, respectively. There were significant lower leukemia-free survival (LFS) (a), event-free survival (EFS) (b) and overall survival (OS) (c) in the low-expression group of miR-210.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317805&req=5

fig03: The prognostic significance of miR-210 in the validation cohort (76 patients). The dashed line and solid line were derived from miR-210 high-expression or low-expression group, respectively. There were significant lower leukemia-free survival (LFS) (a), event-free survival (EFS) (b) and overall survival (OS) (c) in the low-expression group of miR-210.

Mentions: In the validation cohort (n = 76), with median follow-up time of 48.0 months, the poor treatment outcome in the low-expression group was confirmed. Using the above cut-off value, these patients were separated into low-expression and high-expression groups (32 and 44 cases, respectively). During the follow-up period, six patients with low expression of miR-210 and only 1 with high expression suffered from BM relapse or induction failure. The rate of relapse and induction failure was significantly higher (P = 0.037) and the 4-year LFS (log rank: P = 0.014; Fig. 3a), EFS (log-rank: P = 0.046; Fig. 3b) and OS (log rank: P = 0.033; Fig. 3c) were significantly poorer in the low-expression group.


Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.

Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X, Liu F, Wu M, Deng G, Ding W, Jia H, Li Z - Cancer Sci. (2014)

The prognostic significance of miR-210 in the validation cohort (76 patients). The dashed line and solid line were derived from miR-210 high-expression or low-expression group, respectively. There were significant lower leukemia-free survival (LFS) (a), event-free survival (EFS) (b) and overall survival (OS) (c) in the low-expression group of miR-210.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317805&req=5

fig03: The prognostic significance of miR-210 in the validation cohort (76 patients). The dashed line and solid line were derived from miR-210 high-expression or low-expression group, respectively. There were significant lower leukemia-free survival (LFS) (a), event-free survival (EFS) (b) and overall survival (OS) (c) in the low-expression group of miR-210.
Mentions: In the validation cohort (n = 76), with median follow-up time of 48.0 months, the poor treatment outcome in the low-expression group was confirmed. Using the above cut-off value, these patients were separated into low-expression and high-expression groups (32 and 44 cases, respectively). During the follow-up period, six patients with low expression of miR-210 and only 1 with high expression suffered from BM relapse or induction failure. The rate of relapse and induction failure was significantly higher (P = 0.037) and the 4-year LFS (log rank: P = 0.014; Fig. 3a), EFS (log-rank: P = 0.046; Fig. 3b) and OS (log rank: P = 0.033; Fig. 3c) were significantly poorer in the low-expression group.

Bottom Line: We further examined its effect on the response to chemotherapeutic drugs in the Reh and RS4;11 cell lines.A significantly poorer treatment outcome (P < 0.05) was found in the low-expression group and verified in the validation cohort (76 cases, P < 0.05).Increasing/decreasing miR-210 expression using agomir/antagomir could enhance or reduce the response of Reh cells and RS4;11 cells to daunorubicin/dexamethasone/L-asparaginase and daunorubicin/dexamethasone/vincristine, respectively.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Major Diseases in Children (Capital Medical University), Ministry of Education, National Key Discipline of Pediatrics, Ministry of Education, Hematology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.

Show MeSH
Related in: MedlinePlus